Company Overview

Intelligent Bio Solutions Inc. is a medical technology and diagnostics company focused on non-invasive drug screening and biosensor-based testing solutions. The company operates primarily in the workplace safety, healthcare screening, and compliance monitoring sectors, with a commercial emphasis on rapid testing technologies designed to replace or supplement traditional saliva, urine, and blood-based testing methods. Its core commercial platform is the Intelligent Fingerprinting Drug Screening System, which uses fingerprint sweat analysis to detect recent drug use without the need for invasive sample collection.

The company’s principal revenue driver is the sale and deployment of its fingerprint-based drug testing system, including portable readers, consumable test cartridges, and associated screening services. Intelligent Bio Solutions evolved from earlier biosensor and life sciences initiatives and has repositioned its strategy around commercializing rapid diagnostics and workplace screening technologies. Public filings indicate that the company has focused on regulated screening environments where speed, portability, and hygiene are operational advantages, particularly in transportation, manufacturing, logistics, and safety-sensitive industries.

Business Operations

Intelligent Bio Solutions conducts operations through its diagnostics and drug screening activities, centered around the Intelligent Fingerprinting platform and related commercial operations. Revenue is generated through hardware sales, recurring consumable cartridge sales, distribution agreements, and screening-related services. The company’s technology platform is designed to provide point-of-care testing with results delivered in a short timeframe, supporting employers and testing administrators seeking operational efficiency and reduced disruption to workforce screening processes.

The company maintains operations across both domestic and international markets, with commercial activity particularly associated with the United Kingdom, Australia, and parts of Europe. Its controlled assets include proprietary fingerprint drug screening technology, portable reader systems, software integration capabilities, and intellectual property related to biosensor diagnostics. Public disclosures also reference commercial partnerships and distributor relationships used to expand market access. Data regarding material joint ventures or large-scale strategic alliances is limited in publicly available disclosures and may be inconclusive based on available public sources.

Strategic Position & Investments

The company’s strategic direction has centered on expanding adoption of non-invasive testing technologies in workplace and compliance-driven environments. Growth initiatives have included scaling distribution networks, seeking additional regulatory clearances, expanding into new geographic territories, and increasing adoption among transportation, construction, warehousing, and industrial employers. Intelligent Bio Solutions has also emphasized recurring consumable revenue opportunities tied to installed testing systems.

A notable strategic asset is Intelligent Fingerprinting Ltd, which represents the company’s principal operating technology business and commercial platform. The company has invested in further development of fingerprint-based diagnostics and broader biosensor applications, positioning itself within the emerging rapid point-of-care diagnostics market. Public filings and investor materials indicate continued focus on technology validation, customer adoption, and commercialization rather than large-scale diversification into unrelated sectors. Information regarding substantial acquisition activity beyond previously disclosed corporate restructuring and technology-focused transactions is limited.

Geographic Footprint

Intelligent Bio Solutions maintains a multinational operating footprint with corporate activities connected to the United States, United Kingdom, and Australia. The company is publicly listed in the U.S. and has operational and commercial ties to international diagnostics and screening markets. Its fingerprint drug testing technology has been marketed primarily in the UK and selected international jurisdictions where workplace screening and safety compliance standards support demand for rapid testing solutions.

The company’s international presence has been supported through distribution arrangements, channel partners, and commercial expansion initiatives targeting customers across Europe, Asia-Pacific, and other industrial markets. Its operational influence remains relatively specialized and focused on drug screening technology adoption rather than broad healthcare system integration. Publicly available disclosures indicate continued efforts to broaden market penetration internationally while maintaining a concentrated technology-driven business model.

Leadership & Governance

Intelligent Bio Solutions is governed by a board of directors and executive leadership team focused on commercial execution, regulatory advancement, and technology commercialization. Leadership communications in public filings and investor presentations have emphasized operational scalability, customer adoption, and advancement of non-invasive diagnostics technologies. The company’s governance framework reflects standard public-company reporting and oversight practices associated with its U.S. listing obligations and SEC filings.

Key executives and leadership figures include:

• Harry Simeonidis – Executive Chairman
• Doug Heath – Chief Executive Officer
• Michael L. Higgins – Chief Financial Officer
• Yulia Tikhonova – Chief Scientific Officer

Public disclosures indicate that leadership strategy has focused on expanding commercial adoption of the company’s screening platform, strengthening regulatory positioning, and pursuing operational growth through technology-led differentiation in the diagnostics market.